Why Illumina Was Up 17% in June
Shares of Illumina (NASDAQ: ILMN) gained 17% last month, according to S&P Global Market Intelligence. The stock climbed steadily throughout the month after its Grail spinoff presented impressive data from its liquid-biopsy test at the American Society of Clinical Oncology (ASCO) meeting.
The test, called Galleri, is available by prescription and offers screening for more than 50 different types of cancer from a single blood sample. The study was conducted with 6,629 patients aged 50 years or older.
Other companies like Guardant Health and Freenome are also working on liquid biopsies. The tests could transform cancer treatment by catching the disease before any symptoms arise.
Source Fool.com
